Amyris Is Giving the "Hippie Perfume Molecule" a Synthetic Biology Makeover

For the first time in history, patchouli oil will be produced by yeast instead of a plant. Can Amyris cash in on the opportunity?

Apr 24, 2014 at 11:15AM


The patchouli plant, grown for centuries in tropical Asia for use in perfumes, is due for a makeover. Source: Wikimedia Commons / Vieux jardin botanique de Göttingen.

Patchouli is fun to say and more fun to spray. While Urban Dictionary associates the fragrance oil extracted from the leaves of the exotic scented plant with hippie perfume used to mask the scent of the unbathed (among other things), patchouli oil has far more industrial importance in personal-care markets than the humorous definition would lead you to believe. You may find its scent throughout your home in laundry detergents, air fresheners, baby wipes, and more. The oil was even incorporated into a Masters of the Universe action figure sold by Mattel in 1985.

Despite its industrial potential, patchouli oil -- and the broader flavors and fragrances industry -- faces the same problems that plague the market for squalane, a high-value emollient used throughout the cosmetic industry. Current agricultural methods used to produce the molecule result in unreliable, unsustainable, and inconsistent quality of its supply. That's why synthetic biology pioneer Amyris (NASDAQ:AMRS) and Firmenich, the largest flavor and fragrance company, have developed a novel bioprocess for producing large, quality volumes of patchouli oil from yeast.

Ripe for disruption
Patchouli is natively grown by farmers in the tropical regions of Asia, but it was introduced to Europe through trade conducted on the Silk Road. Cultivation methods haven't changed much over the centuries and still follow the same general path to monetization: Farmers grow the crop, harvest the leaves, dry them, and extract patchouli oil at an approximately 3.5% yield. The leaves can be sold before or after being dried, but the selling price captured deteriorates for each additional processing step. For instance, long-term contracts for dried leaves can fetch about $300-$350 per metric ton, but purified patchouli oil can fetch $50 per kilogram.

In other words, it pays to be as close to the end of cultivation process -- extraction -- as possible. The agricultural approach takes six months from planting to the first harvest of leaves, not including drying and extraction. Good news: Amyris has replaced the lengthy cultivation and extraction process with a single manufacturing process that produces pure, high-quality patchouli oil in about two weeks.

The future of flavors and fragrances
Amyris has set some pretty ambitious goals within the flavors and fragrances industry. In all, the company has 22 molecules under contract with the world's leading companies, which could generate roughly $1 billion in revenue by 2020. The opportunity (selling price and volume) varies for each molecule, but the aggregate potential is huge. Take a look at the opportunity presented by six of the 22 molecules currently under contract and their expected market introduction date:


Amyris estimates; not drawn to scale. Source: Amyris.

How does product development work? Firmenich paid Amyris to engineer an organism to produce economical volumes of patchouli oil and scale production at its facility in Brotas, Brazil. Once produced in bulk later this year, Firmenich will pay Amyris for production costs plus a predetermined premium, and both will share in the differential from the market price. The contract structure works because the synthetic biology platform has enabled the lowest production costs for patchouli oil in the world. However, Amyris is incentivized to optimize production metrics to increase its profits from the contract -- as well as future contracts -- which could generate 60%-70% gross margins, according to CEO John Melo.

Foolish bottom line
Amyris' platform (based on the isoprenoid metabolic pathway) can target about $1 billion of the $6 billion annual market for flavors and fragrances, which is growing at a CAGR of 5% annually. Despite partnerships and development agreements with the world's leading flavor and fragrance companies, it's important to keep your expectations in check. There are several synthetic biology start-ups and organism companies targeting flavor and fragrance molecules that lie outside of Amyris' platform. A few synthetic chemical producers are beginning to develop processes for creating the high-value molecules, too. There is bound to be overlap (and thus competition for Amyris), but then again, novel production systems that offer reliable supply should lead to a global expansion of the market opportunity for each molecule.

A successful launch of patchouli oil in 2014 would add to the developmental flexibility of Amyris and could allow it to develop additional molecules more quickly. However, while successfully producing one molecule out of 22 contracted molecules does not guarantee success across the platform, it would certainly bring the company one step closer to profitability. Investors are still quite some time away from learning if the company will hit its goal of $1 billion in revenue from its current pipeline of molecules (not including tire applications). Whether or not that occurs, I believe there is plenty of room for growth from the base of $15.8 million in product revenue generated in 2013.

Is Amyris poised for incredible growth?
I believe so, but the risks should factor heavily into your decision. If they're too much, perhaps you should lean on the investing wisdom of David Gardner. Just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.

Maxx Chatsko owns shares of Amyris. Check out his personal portfolio, his CAPS page, his previous writing for The Motley Fool, or his work for SynBioBeta to keep up with developments in the synthetic biology industry.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers